Acinetobacter baumannii response to cefiderocol challenge in human urine

Acinetobacter baumannii response to cefiderocol challenge in human urine

Abstract Cefiderocol (CFDC) is a novel chlorocatechol-substituted siderophore antibiotic approved to treat complicated urinary tract infections (cUTI) and hospital-acquired and ventilator-acquired pneumonia (HAP/VAP). Previous work determined that albumin-rich human fluids increase the minimum inhib...

Full description

Bibliographic Details
Main Authors: Brent Nishimura, Jenny Escalante, Marisel R. Tuttobene, Tomás Subils, Vyanka Mezcord, Camila Pimentel, Nardin Georgeos, Fernando Pasteran, Cecilia Rodriguez, Rodrigo Sieira, Luis A. Actis, Marcelo E. Tolmasky, Robert A. Bonomo, María Soledad Ramirez
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-12829-7

Internet

https://doi.org/10.1038/s41598-022-12829-7

Similar Items